Wechsler is the former CEO of Smile Brands and senior executive at Bausch & Lomb, Merck and Pfizer

Dan Wechsler is the new Executive Chairman of NavaDerm Partners, a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm.

Wechsler served as President and CEO of Smile Brands, a privately held dental service organization with 4,500 employees (including 700 general and specialty dentists) and more than 360 offices. Prior to Smile Brands, he served as EVP and Global President of Pharmaceuticals at Bausch + Lomb. Dan was previously an executive at Merck & Co., Schering-Plough, Pfizer Inc., Melinta Therapeutics, and The Upjohn Company. Wechsler holds a Master of Philosophy from University of Rochester, as well as a B.A. from the State University of New York at Brockport.

 "I am excited to join NavaDerm and help support, [NavaDerm CEO and Board Director] Dr. John Murphy and our outstanding physician partners in building a world-class dermatology platform. NavaDerm's focus on providing superior clinical care and partnering with the top dermatologists in the Northeast is a differentiated strategy that is resonating in the market. I look forward to building upon the already strong corporate foundation and helping guide NavaDerm through its next growth phase," he says.

Dr. Murphy adds, "We are thrilled to have Dan join NavaDerm.  Dan is a seasoned practice management and pharma executive and we are fortunate to have someone of his caliber join our team. We are building a best-in-class corporate organization to support our outstanding dermatologists and Dan's experience in scaling organizations will be invaluable as we continue to execute on our plan. We are focused on accelerating growth while maintaining our core mission - partnering with terrific dermatologists and their dedicated staffs and support them in providing exceptional patient care."